TY - JOUR
T1 - Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer
AU - Morgan, R. J.
AU - Doroshow, J. H.
AU - Leong, L.
AU - Schriber, J.
AU - Shibata, S.
AU - Forman, S.
AU - Hamasaki, V.
AU - Margolin, K.
AU - Somlo, G.
AU - Alvarnas, J.
AU - McNamara, M.
AU - Longmate, J.
AU - Raschko, J.
AU - Chow, W.
AU - Vasilev, S.
AU - McGonigle, K.
AU - Yen, Y.
PY - 2001/12/13
Y1 - 2001/12/13
N2 - This study was performed in order to evaluate the toxicities, progression-free and overall survival of patients with responsive residual or recurrent ovarian cancer treated with high-dose chemotherapy. Twenty-seven patients were treated. Doxorubicin, 165 mg/m2 over 96 h (days -12 to -8), etoposide 700 mg/m2 every day ×3 (days -6 to -4), and cyclophosphamide 4.2 g/m2 on d -3 was followed by stem cells and granulocyte colony-stimulating factor. The median days of granulocyte count <500/μl was 14 (range 10-42) and platelets <20 000/μl was 13 (range 2-80). Median numbers of red cell and platelet transfusions were 15 (5-16) and 14 (4-103). Toxicity included mucositis requiring narcotic analgesia in all patients. Asymptomatic decreases in ejection fraction to values <50% were observed in four patients. No clinical congestive heart failure was observed. One death due to sepsis was observed. Median progression-free survival is 7.5 months (1.0-56 months); five patients remain alive, two of whom remain progression-free at 19.5 and 24.5 months post transplant. Median overall survival is 14.0 months (1-68 months). We conclude that high-dose anthracyclines may be safely administered to ovarian cancer patients. The short overall and progression-free survivals observed in our population suggest that this combination is not optimal.
AB - This study was performed in order to evaluate the toxicities, progression-free and overall survival of patients with responsive residual or recurrent ovarian cancer treated with high-dose chemotherapy. Twenty-seven patients were treated. Doxorubicin, 165 mg/m2 over 96 h (days -12 to -8), etoposide 700 mg/m2 every day ×3 (days -6 to -4), and cyclophosphamide 4.2 g/m2 on d -3 was followed by stem cells and granulocyte colony-stimulating factor. The median days of granulocyte count <500/μl was 14 (range 10-42) and platelets <20 000/μl was 13 (range 2-80). Median numbers of red cell and platelet transfusions were 15 (5-16) and 14 (4-103). Toxicity included mucositis requiring narcotic analgesia in all patients. Asymptomatic decreases in ejection fraction to values <50% were observed in four patients. No clinical congestive heart failure was observed. One death due to sepsis was observed. Median progression-free survival is 7.5 months (1.0-56 months); five patients remain alive, two of whom remain progression-free at 19.5 and 24.5 months post transplant. Median overall survival is 14.0 months (1-68 months). We conclude that high-dose anthracyclines may be safely administered to ovarian cancer patients. The short overall and progression-free survivals observed in our population suggest that this combination is not optimal.
KW - High-dose chemotherapy
KW - Ovarian cancer
KW - Stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=0035201069&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035201069&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1703243
DO - 10.1038/sj.bmt.1703243
M3 - Article
C2 - 11781646
AN - SCOPUS:0035201069
VL - 28
SP - 859
EP - 863
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 9
ER -